) AKT2 is a member of the Akt/protein kinase B family and is activated in response to phosphatidylinositol 3-kinase (PI 3-K)-mediated signals triggered at the cell membrane by growth factors. Amplification and/or overexpression of the AKT2 oncogene are associated with the development of human ovarian carcinomas. Therefore, understanding the role of AKT2 and PI 3-K-mediated signals in the growth regulation of human ovarian surface epithelial (HOSE) cells will contribute to a better understanding of the molecular mechanisms underlying ovarian oncogenesis, which is the broad, long-term objective of this project.
The specific aims are: (1) Determine the involvement of AKT2, the related AKT1, and PI 3-K in human ovarian cancer. Examine the expression/kinase activity of AKT2, AKT1, and the catalytic subunit of PI 3-K (p110 alpha) in ovarian carcinoma specimens, and their expression in premalignant lesions in women predisposed to ovarian cancer. Correlate these laboratory findings with various clinicopathologic parameters to determine their clinical relevance. (2) Characterize the role of AKT2 in the regulation of physiological and neoplastic growth of HOSE cells in vitro. Evaluate the effect of the expression and/or activity of AKT2 on growth rate, cell cycle progression, and the induction of apoptosis. Using cDNA expression arrays, identify groups of genes associated with ovarian oncogenesis, whose expression is regulated in response to AKT2 expression/activity. (3) Determine the role of AKT2 in invasion and metastasis of HOSE cells and ovarian cancer cells. Using conditional retroviral expression constructs, investigate the potential involvement of AKT2 expression/activity in cell survival and the development of more invasive or metastatic phenotypes. (4) Identify modulators and substrates of AKT2. Using the yeast two-hybrid system and ovarian cancer-specific phage cDNA expression libraries, identify proteins that interact with AKT2 in the transduction of mitogenic signals in ovarian cancer cells, and determine the physiological significance of these interactions in HOSE cells. Overall, the studies proposed here will provide important new insights regarding the mechanisms by which AKT2 and PI 3-K-mediated signals contribute to ovarian oncogenesis, and may create potential avenues for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083638-01S1
Application #
6323313
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1999-09-30
Project End
2000-09-29
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
$55,474
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Chiang, Cheryl Lai-Lai; Kandalaft, Lana E (2018) In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 71:88-101
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757
Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198

Showing the most recent 10 out of 323 publications